{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:40Z","timestamp":1781560120317,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clinthera.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T08:02:47Z","timestamp":1490947367000},"page":"771-786.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain"],"prefix":"10.1016","volume":"39","author":[{"given":"Guillermo","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Lothgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Kutikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben van","family":"Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.02.011_bib1","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/eurheartj\/ehu299","article-title":"Cardiovascular disease in Europe 2014: epidemiological update","volume":"35","author":"Nichols","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.02.011_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1741826710389393","article-title":"Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in Europe","volume":"18","author":"Bertuccio","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.clinthera.2017.02.011_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.02.011_bib4","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.02.011_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.02.011_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.02.011_bib7","first-page":"140","article-title":"Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.clinthera.2017.02.011_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.02.011_bib9","unstructured":"European Medicines Agency. Repatha. EMEA\/H\/C\/003766. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003766\/human_med_001890.jsp&mid=WC0b01ac058001d124. Accessed March 29, 2016."},{"key":"10.1016\/j.clinthera.2017.02.011_bib10","year":"2016","journal-title":"Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia"},{"key":"10.1016\/j.clinthera.2017.02.011_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2017.02.011_bib12","series-title":"Public Policy and the Challenge of Chronic Noncommunicable Diseases","author":"Adeyi","year":"2007"},{"key":"10.1016\/j.clinthera.2017.02.011_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)61696-1","article-title":"The burden and costs of chronic diseases in low-income and middle-income countries","volume":"370","author":"Abegunde","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.02.011_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.02.011_bib15","series-title":"Applied Methods of Cost-effectiveness Analysis in Healthcare","author":"Gray","year":"2010"},{"key":"10.1016\/j.clinthera.2017.02.011_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.02.011_bib17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.02.011_bib18","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.02.011_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.02.011_bib20","first-page":"617","article-title":"SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research [in Spanish]","volume":"138","author":"Bolibar","year":"2012"},{"key":"10.1016\/j.clinthera.2017.02.011_bib21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1161\/HYPERTENSIONAHA.115.05198","article-title":"Incident atrial fibrillation hazard in hypertensive population: a risk function from and for clinical practice [published retraction appears in Hypertension. 2016;67:e23]","volume":"65","author":"Alves-Cabratosa","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2017.02.011_bib22","doi-asserted-by":"crossref","first-page":"e109706","DOI":"10.1371\/journal.pone.0109706","article-title":"Linking of primary care records to census data to study the association between socioeconomic status and cancer incidence in Southern Europe: a nation-wide ecological study","volume":"9","author":"Garcia-Gil","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2017.02.011_bib23","article-title":"Tasas de incidencia de enfermedad coronaria en pacientes con antecedentes de insuficiencia cardiaca (ICC). Jornadas Cardiovasculares SEMERGEN (Internet)","author":"Garcia-Gil","year":"2016","journal-title":"SEMERGEN Santander"},{"key":"10.1016\/j.clinthera.2017.02.011_bib24","article-title":"Tasas de incidencia de enfermedad coronaria en pacientes con antecedentes de ictus isqu\u00e9mico (IS). Jornadas Cardiovasculares SEMERGEN (Internet)","author":"Garcia-Gil","year":"2016","journal-title":"SEMERGEN Santander"},{"key":"10.1016\/j.clinthera.2017.02.011_bib25","article-title":"Tasas de incidencia de enfermedad coronaria en pacientes con antecedentes de enfermedad coronaria (EC). Jornadas Cardiovasculares SEMERGEN (Internet)","author":"Ramos","year":"2016","journal-title":"SEMERGEN Santander"},{"key":"10.1016\/j.clinthera.2017.02.011_bib26","article-title":"Tasas de incidencia de enfermedad coronaria en pacientes con antecedentes de enfermedad cardiovascular establecida (ECVE). Jornadas Cardiovasculares SEMERGEN (Internet)","author":"Ramos","year":"2016","journal-title":"SEMERGEN Santander"},{"key":"10.1016\/j.clinthera.2017.02.011_bib27","unstructured":"Instituto Nacional de Estad\u00edstica. http:\/\/www.ine.es\/. Accessed March 29, 2016."},{"key":"10.1016\/j.clinthera.2017.02.011_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.02.011_bib29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2017.02.011_bib30","doi-asserted-by":"crossref","first-page":"A338","DOI":"10.1016\/j.jval.2015.09.129","article-title":"Avoiding overestimation in annualization of event risk from risk functions for use in economic modeling","volume":"18","author":"Lothgren","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.02.011_bib31","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.clinthera.2016.05.006","article-title":"Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature","volume":"38","author":"Wong","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.02.011_bib32","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.02.011_bib33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.02.011_bib34","year":"2013","journal-title":"Guideline on clinical investigation of medicinal products in the treatment of lipid disorders [Internet]"},{"key":"10.1016\/j.clinthera.2017.02.011_bib35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.02.011_bib36","year":"2016","journal-title":"Premeeting briefing \u2013 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia"},{"key":"10.1016\/j.clinthera.2017.02.011_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(15)61351-1","article-title":"A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145)","volume":"65","author":"Toth","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.02.011_bib38","series-title":"Self-Reported Population Health: An International Perspective based on EQ-5D","author":"Szende","year":"2014"},{"key":"10.1016\/j.clinthera.2017.02.011_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","article-title":"Acute and chronic impact of cardiovascular events on health state utilities","volume":"15","author":"Matza","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2017.02.011_bib40","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Portalfarma. https:\/\/botplusweb.portalfarma.com. Accessed March 29, 2016."},{"key":"10.1016\/j.clinthera.2017.02.011_bib41","article-title":"Coste de eventos cardiovasculares en espa\u00f1a: Una revisi\u00f3n de literatura","author":"Planellas","year":"2015","journal-title":"XXXV Jornadas de la Asociaci\u00f3n de Econom\u00eda de la Salud (AES), Granada"},{"key":"10.1016\/j.clinthera.2017.02.011_bib42","first-page":"154","article-title":"A proposed guideline for economic evaluation of health technologies [in Spanish]","volume":"24","author":"Lopez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.clinthera.2017.02.011_bib43","doi-asserted-by":"crossref","unstructured":"De Cock E, M M, JR G, Azanza-Perea J. Valor umbral del coste por a\u00f1o de vida ganado para recomendar la adopci\u00f3n de tecnolog\u00edas sanitarias en Espa\u00f1a: evidencias procedentes de una revisi\u00f3n de la literature. Pharmacoeconomics. 4:97\u2013107.","DOI":"10.1007\/BF03320930"},{"key":"10.1016\/j.clinthera.2017.02.011_bib44","first-page":"334","article-title":"What is an efficient health technology in Spain? [in Spanish]","volume":"16","author":"Sacristan","year":"2002","journal-title":"Gac Sanit"},{"key":"10.1016\/j.clinthera.2017.02.011_bib45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T12:33:32Z","timestamp":1568982812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817301327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0149291817301327"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}